<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04353648</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00103143</org_study_id>
    <nct_id>NCT04353648</nct_id>
  </id_info>
  <brief_title>Assessing Muscle Metabolic Phenotype by MSK Ultrasound</brief_title>
  <official_title>Assessment of Muscle Metabolic Phenotype by the Use of Point-of-care MSK Ultrasound Imaging.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test whether ultrasound images (pictures) can be used as a&#xD;
      valid assessment of muscle quality in different muscle groups during Intensive Care stay.&#xD;
      This new approach would allow clinicians to obtain frequent skeletal muscle images and would&#xD;
      enable doctors to observe any changes over time in muscle quality that could occur during ICU&#xD;
      stay.&#xD;
&#xD;
      Participants in this study will have ultrasound images made of their leg-, chest- and jaw&#xD;
      muscles taken on every day until ICU discharge.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Suspended due to COVID-19&#xD;
  </why_stopped>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Anticipated">October 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Muscle Quality from the rectus femoris, vastus lateralis, intermedius, intercostalis, temporalis and styloglossus</measure>
    <time_frame>Minimum of every other day while in ICU (up to 10 days). Once discharged from ICU minimum of 3x a week until discharge (up to 3 weeks)</time_frame>
    <description>Ultrasound-derived area of intramuscular adipose tissue (IMAT) and intramuscular glycogen content from the rectus femoris, vastus lateralis, intermedius, intercostalis, temporalis and styloglossus</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Muscle volume and thickness from the rectus femoris, vastus lateralis, intermedius, intercostalis, temporalis and styloglossus</measure>
    <time_frame>Minimum of every other day while in ICU (up to 10 days). Once discharged from ICU minimum of 3x a week until discharge (up to 3 weeks)</time_frame>
    <description>Ultrasound-derived volume and thicknessfrom the rectus femoris, vastus lateralis, intermedius, intercostalis, temporalis and styloglossus</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of Intramuscular adipose tissue (IMAT) content and muscle volume/thickness from the psoas at the Level of L3/L4</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>the change over time of (standard of care) CT-derived area of intramuscular adipose tissue in cm2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Intramuscular adipose tissue (IMAT) content and muscle volume/thickness from the intercostal muscle at the Level of Th3/Th4</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>the change over time of (standard of care) CT-derived area of intramuscular adipose tissue in cm2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Intramuscular adipose tissue (IMAT) content and muscle volume/thickness from the intercostal muscle at the Level of the head</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>the change over time of (standard of care) CT-derived area of intramuscular adipose tissue in cm2</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Ultrasound</condition>
  <arm_group>
    <arm_group_label>Duke ICU/Trauma Center Patients</arm_group_label>
    <description>Any patient admitted to the Duke Trauma Center or Duke ICU will be approached to participate in this study.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All patients admitted to a Duke Trauma center, SICU, MICO, or CT ICU&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  admission Duke Trauma center, SICU, MICU, or CT ICU&#xD;
&#xD;
          -  &gt;18 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &lt;18 years of age&#xD;
&#xD;
          -  prisoners&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Wischmeyer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 14, 2020</study_first_submitted>
  <study_first_submitted_qc>April 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2020</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

